DEP phase 2 trials - patience required!, page-3

Hi Domesticgod

I acknowledge your concerns in my first couple of paragraphs regarding the disappointments and management's failings regarding viraleze and vivagel. I feel everyone's pain and empathise with them. My main discussion point is regarding the phase 2 trials: that management shouldn't be expected to rush towards likely multi- billion dollar deals. The data has to be allowed to mature to get to the point of maximum value. With more mature ( very good) data, other benefits could also come into play, such as expedited approvals, etc. I really don't think management should be criticised at this point - at least not until we see how it plays out.
My main motivation is to try to reassure those who are hurting that, if they can hold on, things are likely to get a whole lot better. I hate reading posts from long term holders saying they have had enough and are selling out. It makes me feel bad for them that they may be baling out so close to the finish line and (IMHO) the major prize.